Literature DB >> 8379727

Management of lymphoproliferative disorders after cardiac transplantation.

J M Chen1, M L Barr, A Chadburn, G Frizzera, F A Schenkel, R R Sciacca, D S Reison, L J Addonizio, E A Rose, D M Knowles.   

Abstract

We conducted a retrospective study of 516 cardiac recipients who underwent transplantation between April 1983 and April 1992, 19 of whom had development of post-transplantation lymphoproliferative disorders (PTLDs). These 19 patients presented with involvement of lung (5), gastrointestinal tract (5), disseminated disease (6), and adenoids and lymph nodes (3). B-cell proliferations ranging from an atypical hyperplasia to malignant lymphoma developed in 18 patients, and mixed cellularity Hodgkin's disease developed in 1 patient. The 19 patients with PTLD displayed a predominance of both women and cardiomyopathy as the indication for transplantation when compared with two separate control populations. No correlation was found between demographic criteria analyzed and (1) early versus late diagnosis of PTLD after transplantation, (2) the site of PTLD involvement, or (3) the histopathologic category of the PTLD lesion. Patients with gastrointestinal tract and lung PTLD involvement enjoyed an improved survival after both transplantation and PTLD diagnosis when compared with patients with PTLD involvement of all other extranodal sites. We report a high incidence of PTLD involving the lung and gastrointestinal tract in our cohort study. These sites of involvement responded better to a reduction in immunosuppression than did the other extranodal sites of involvement.

Entities:  

Mesh:

Year:  1993        PMID: 8379727     DOI: 10.1016/0003-4975(93)90893-m

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  The mother lode of liver transplantation, with particular reference to our new journal.

Authors:  T E Starzl
Journal:  Liver Transpl Surg       Date:  1998-01

2.  Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.

Authors:  M A Nalesnik; A S Rao; A Zeevi; J J Fung; S Pham; H Furukawa; A Gritsch; G Klein; T E Starzl
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

3.  Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

Authors:  R Reshef; S Vardhanabhuti; M R Luskin; D F Heitjan; D Hadjiliadis; S Goral; K L Krok; L R Goldberg; D L Porter; E A Stadtmauer; D E Tsai
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

Review 4.  Cutaneous T-cell lymphoma in a cardiac transplant recipient.

Authors:  D M McMullan; B Radovaneević; C M Jackow; O H Frazier; M Duvic
Journal:  Tex Heart Inst J       Date:  2001

Review 5.  Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD).

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Post-transplant lymphoproliferative disorders.

Authors:  K J Lewin
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

7.  Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.

Authors:  A Chadburn; N Suciu-Foca; E Cesarman; E Reed; R E Michler; D M Knowles
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 8.  The post-transplant lymphoproliferative disorder-a literature review.

Authors:  Rokshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714

9.  Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.

Authors:  J Setsuda; J Teruya-Feldstein; N L Harris; J A Ferry; L Sorbara; G Gupta; E S Jaffe; G Tosato
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 10.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.